Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Lotiglipron in T2DM with Renal Impairment
NCT05510245Phase 1Terminated
- Sponsor
- Pfizer
- Start
- Aug 2022
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of lotiglipron in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Pfizer. Primary endpoints: Maximum Observed Concentration at 144 hours, Unbound Maximum Observed Concentration at Day 1 and 3 more. Started Aug 2022; status: terminated.
02
Drugs
lotiglipron
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05510245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05510245.